MyFinsight
Home
Blog
About
Cash and cash
equivalents
$30,118K
(-46.34%↓ Y/Y)
Research and development
incentives receivables
$1,683K
(-38.82%↓ Y/Y)
Prepaid expenses and
other current assets
$1,600K
(-37.13%↓ Y/Y)
Property and equipment,
at cost
$1,072K
(-19.28%↓ Y/Y)
Total current assets
$33,401K
(-45.62%↓ Y/Y)
Operating lease
right-of-use assets, net
$1,003K
(92.15%↑ Y/Y)
Intangible assets, net
$256K
(-45.53%↓ Y/Y)
Property and equipment,
net
$54K
(-75.23%↓ Y/Y)
Less accumulated
depreciation
$1,018K
(-8.29%↓ Y/Y)
Total assets
$34,714K
(-44.57%↓ Y/Y)
Total liabilities and
shareholders' equity
$34,714K
(-44.57%↓ Y/Y)
Total shareholders'
equity
$28,652K
(-47.11%↓ Y/Y)
Total liabilities
$6,062K
(-28.29%↓ Y/Y)
Accumulated deficit
-$514,543K
(-5.73%↓ Y/Y)
Accumulated other
comprehensive loss
-$12,285K
(-42.14%↓ Y/Y)
Additional paid-in capital
$552,335K
(1.10%↑ Y/Y)
Total current
liabilities
$5,677K
(-24.88%↓ Y/Y)
Other non-current
liabilities
$370K
(5.11%↑ Y/Y)
Warrant liabilities -
non-current
$15K
(-97.25%↓ Y/Y)
Ordinary shares, par
value 0.003 per share...
$3,145K
(0.42%↑ Y/Y)
Accrued expenses
$2,455K
(-51.30%↓ Y/Y)
Accounts payable
$1,121K
(-1.49%↓ Y/Y)
Other current
liabilities
$1,071K
(37.84%↑ Y/Y)
Operating lease
liabilities - current
$1,030K
(71.38%↑ Y/Y)
Back
Back
Balance Sheet
Mereo BioPharma Group plc (MREO)
Mereo BioPharma Group plc (MREO)
source: myfinsight.com